Hi Eqz ...yes absolutely agree with what you say ...
This is a detailed report that has been based on conservative assumptions as far as revenue
....being a broker report that's understandable...I must admit reading the report...well, lets say
it's was hard to keep my feet on the ground...noticed that throughout the report there are
references to events that will likely make significant gains in the SP......a few are not
that distant.... Eqz..I also picked up on that sales to the US are " full steam ahead "...using
the LDT version of the test PIQ can circumvent FDA ...in fact this strategy , as I understand
it, will be used in other regions around the world ....
Regarding the issue of Reimbursetment...I would definitely agree that sales of Pd would be
achieved at a much faster rate if successful..however ....apart from the benefits to individuals
who use Pd...there is a greater collective problem and that is the costs of CKD where Govt
and healthcare are being increasingly burden and it's happening around the globe now...
this will drive PD in the coming year/s...imo
The report outlines the process for an application for a CPT code....PIQ put in the application
some months ago and we were told 3 months ...technically speaking PIQ are correct....the
initial CPT process is quite straight forward and is given a 3 month timeline...the follow on
meetings with Insurers to make sure the codes will be covered by Insurers and then meeting
with CMS to establish a broad adoption code ...the final part of the process involves
seeking NCD ( National Coverage Determination ) ...6-9 month process ...joining the dots ...
most likely this is what we are waiting for ...an NCD read appendix C...at the end of the report...
glta
- Forums
- ASX - By Stock
- PIQ
- Research report and Initiation of coverage by Euroz
PIQ
proteomics international laboratories ltd
Add to My Watchlist
6.15%
!
30.5¢

Research report and Initiation of coverage by Euroz, page-5
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
30.5¢ |
Change
-0.020(6.15%) |
Mkt cap ! $49.87M |
Open | High | Low | Value | Volume |
33.5¢ | 34.5¢ | 28.5¢ | $201.7K | 642.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3253 | 30.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
33.0¢ | 57411 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3253 | 0.305 |
1 | 10172 | 0.295 |
1 | 150000 | 0.285 |
2 | 29500 | 0.280 |
3 | 141892 | 0.275 |
Price($) | Vol. | No. |
---|---|---|
0.330 | 57411 | 2 |
0.350 | 20000 | 1 |
0.355 | 2498 | 1 |
0.360 | 35000 | 1 |
0.370 | 38750 | 1 |
Last trade - 16.10pm 25/06/2025 (20 minute delay) ? |
Featured News
PIQ (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
SPONSORED BY The Market Online